Study protocol of a German multi-center, observer-blind, randomized, and actively controlled parallel-group trial comparing maintenance electroconvulsive therapy to treatment as usual for relapse prevention in clozapine resistant schizophrenia

Schizophrenia is one of the most severe and costly mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current gold standard in these cases. Electroconvulsive therapy (ECT) is well-known...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Deicher, Anton (VerfasserIn) , Karl, Sebastian (VerfasserIn) , Otte, Marie-Luise (VerfasserIn) , Knabbe, Johannes (VerfasserIn) , Wendel, Bernadette (VerfasserIn) , Gose, Maria (VerfasserIn) , Wolf, Robert Christian (VerfasserIn) , Sartorius, Alexander (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 26 May 2025
In: BMC psychiatry
Year: 2025, Jahrgang: 25, Heft: 1, Pages: 1-7
ISSN:1471-244X
DOI:10.1186/s12888-025-06990-2
Online-Zugang:kostenfrei
kostenfrei
Volltext
Verfasserangaben:Anton Deicher, Sebastian Karl, Marie-Luise Otte, Johannes Knabbe, Bernadette Wendel, Maria Gose, R. Christian Wolf and Alexander Sartorius
Beschreibung
Zusammenfassung:Schizophrenia is one of the most severe and costly mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current gold standard in these cases. Electroconvulsive therapy (ECT) is well-known to be highly effective in clozapine-treatment-resistant schizophrenia (CRS), and synergistic effects of clozapine and ECT have been demonstrated. However, relapse rates after successful courses of ECT are still very high, and evidence for maintenance ECT (mECT) in CRS is scarce at best.
Beschreibung:Gesehen am 02.09.2025
Beschreibung:Online Resource
ISSN:1471-244X
DOI:10.1186/s12888-025-06990-2